Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Motavizumab> ?p ?o. }
Showing items 1 to 43 of
43
with 100 items per page.
- Motavizumab abstract "Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.".
- Motavizumab atcPrefix "J06".
- Motavizumab atcSuffix "BB17".
- Motavizumab casNumber "677010-34-3".
- Motavizumab fdaUniiCode "50Y163LK8Q".
- Motavizumab wikiPageExternalLink www.medimmune.com.
- Motavizumab wikiPageID "9680191".
- Motavizumab wikiPageRevisionID "597843199".
- Motavizumab atcPrefix "J06".
- Motavizumab atcSuffix "BB17".
- Motavizumab c "6476".
- Motavizumab casNumber "677010".
- Motavizumab chemspiderid "NA".
- Motavizumab h "10014".
- Motavizumab hasPhotoCollection Motavizumab.
- Motavizumab kegg "D06621".
- Motavizumab mabType "mab".
- Motavizumab molecularWeight "Approximately 148 kDa".
- Motavizumab n "1706".
- Motavizumab o "2008".
- Motavizumab proteinBound "None".
- Motavizumab routesOfAdministration "i.v.".
- Motavizumab s "48".
- Motavizumab source "zu/o".
- Motavizumab target "RSV glycoprotein F".
- Motavizumab tradename "Numax".
- Motavizumab type "mab".
- Motavizumab unii "50".
- Motavizumab verifiedfields "changed".
- Motavizumab verifiedrevid "458284116".
- Motavizumab watchedfields "changed".
- Motavizumab subject Category:AstraZeneca.
- Motavizumab type Drug.
- Motavizumab type DrugProduct.
- Motavizumab type FunctionalSubstance.
- Motavizumab comment "Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants. As of September 2009, it is undergoing Phase II and III clinical trials.In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision.".
- Motavizumab label "Motavizumab".
- Motavizumab label "موتافيزوماب".
- Motavizumab sameAs m.02pnzfv.
- Motavizumab sameAs Q6917147.
- Motavizumab sameAs Q6917147.
- Motavizumab wasDerivedFrom Motavizumab?oldid=597843199.
- Motavizumab isPrimaryTopicOf Motavizumab.